Method, device, and system to control pH in pulmonary tissue of a subject

1. A method for modulating pH of a virus-infected pulmonary tissue in a mammalian or avian subject to treat a pulmonary viral infectious disease comprising:

generating an aerosol dose of the pharmaceutical composition from an aerosol generator to contact the virus-infected pulmonary tissue in the subject with a pharmaceutical composition including at least one agent, wherein the pharmaceutical composition includes a membrane selective for the charged ion and is configured to achieve a selected pH of the pulmonary tissue, wherein the membrane selective for the charged ion includes liposome membranes of two or more distinct and non-overlapping particle size ranges configured to contact two or more levels of the pulmonary tissue, wherein a first particle size of the two or more distinct and non-overlapping particle size ranges contacts an upper airway passage of the pulmonary tissue in the subject and a second particle size of the two or more distinct and non-overlapping particle size ranges contacts a lower airway passage of the pulmonary tissue in the subject, and

operably coupling the aerosol generator to at least one of a heating, ventilation, or air conditioning system to allow delivery of the aerosol dose of the pharmaceutical composition through the system.

2. The method of claim 1 , wherein the selected pH of the pulmonary tissue is basic.

3. The method of claim 1 , wherein the selected pH of the pulmonary tissue ranges from about 6.5 to 7.5.

4. The method of claim 1 , wherein the membrane is configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue.

5. The method of claim 1 , wherein the pharmaceutical composition including the membrane is transmitted based upon an existing pH of the pulmonary tissue.

6. The method of claim 1 , wherein the charged ion is released based upon an existing pH of the pulmonary tissue.

7. The method of claim 1 , wherein membrane integrity is broken based upon an existing pH of the pulmonary tissue.

8. The method of claim 4 , wherein a sensor is configured to monitor the sensed condition in the pulmonary tissue of the subject.

9. The method of claim 8 , wherein the sensor is configured to monitor at least one of pH of the pulmonary tissue or pH of an exhalant.

10. The method of claim 8 , wherein the sensor is configured to monitor at least one of humidity of an exhalant, temperature, breathing rate, peak rate of exhalation, tidal volume, vital capacity, inspiratory capacity, expiratory reserve volume, or residual volume.

11. The method of claim 8 , wherein a controller responsive to the sensor is configured to selectively control delivery of the charged ion to the pulmonary tissue.

12. The method of claim 11 , wherein the controller is configured to selectively control delivery of the membrane particle size range.

13. The method of claim 11 , wherein the controller is configured to selectively control delivery of one or more membrane particle size ranges.

14. The method of claim 11 , wherein the controller is configured to deliver one or more membrane particles of the selected pH.

15. The method of claim 9 , wherein the pH-monitoring sensor is in an airway passage of the subject.

16. The method of claim 9 , wherein the pH-monitoring sensor is in a sinus or a nostril of the subject.

17. The method of claim 8 , further comprising sensing an environmental condition wherein the pharmaceutical composition is administered in response to the sensed environmental condition.

18. The method of claim 17 , wherein the sensed environmental condition includes a potentially infectious environment.

19. The method of claim 1 , wherein the pulmonary tissue includes an epithelial tissue, mesenchymal tissue, or endothelial tissue.

20. The method of claim 1 , further comprising administering the pharmaceutical composition to oropharynx tissue or nasopharynx tissue.

21. The method of claim 1 , further comprising administering the pharmaceutical composition to trachial tissue.

22. The method of claim 1 , wherein the pulmonary tissue includes bronchial, bronchiole, alveolar duct, or alveoli tissue.

23. The method of claim 1 , wherein the charged ion includes a cation.

24. The method of claim 23 , wherein the cation includes H + , K + , or Mg 2+ .

25. The method of claim 1 , wherein the charged ion includes an anion.

26. The method of claim 25 , wherein the anion includes phosphate, citrate, lactate, pyruvate, or an organic acid.

27. The method of claim 1 , wherein the pharmaceutical composition includes a buffering agent.

28. The method of claim 27 , wherein the buffering agent includes at least one of a phosphate buffer, citrate buffer, lactate buffer, pyruvate buffer, or an organic acid buffer.

29. The method of claim 9 , wherein the liposome membrane is configured to communicate to the pH-monitoring sensor.

30. The method of claim 29 , wherein the liposome membrane releases a basic agent, an acidic agent or a buffering agent or combination thereof indicating a pH range, and the pH-monitoring sensor is configured to recognize the marker.

31. The method of claim 1 , wherein the pharmaceutical composition is administered orally or nasally.

32. The method of claim 1 , wherein the pharmaceutical composition is administered as a continuous or pulsatile dose of the pharmaceutical composition.

33. The method of claim 1 , comprising delivering the aerosol dose of the pharmaceutical composition to one or more subjects in an enclosed space.

34. The method of claim 1 , wherein the pharmaceutical composition is configured to provide a timed-release of the charged ion.

35. The method of claim 1 , wherein the pharmaceutical composition is configured to provide an extended release form of the charged ion.

36. The method of claim 1 , wherein the pharmaceutical composition is a liquid or a powder.